



### **Matthew Bottomley**

Matthew Bottomley is Function Head of Vaccine Design & Characterization at GSK, Maryland, USA, where he leads a team of 15 pre-clinical research scientists. Matthew grew up in the UK and was awarded his first degree in Biochemistry at Trinity College, University of Oxford. He obtained his PhD in Structural Biology at University College London. He was awarded European fellowships to perform post-doctoral research at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and at the Istituto di Ricerche di Biologia Molecolare in Rome, Italy, which led to numerous scientific advances and publications. Indeed, he became a firm believer in the value of mobility in research and has supervised several trans-European junior scientists. Since 2010, Matthew has worked in the field of vaccine research to protect humans against infectious diseases. In particular, he has pioneered the use of three-dimensional (3D) structural biology information in the design of new vaccine antigens, an approach termed Structural Vaccinology. Matthew has published research findings for vaccines against numerous pathogens, including *Staphylococcus aureus*, *Clostridium difficile*, Groups A and B *streptococcus*, and respiratory syncytial virus (RSV), and is proud to have worked on the team that developed the first approved genome-derived recombinant protein vaccine against serogroup B *Neisseria meningitidis*. Matthew's professional ambition is to help improve global human health by design of innovative effective vaccines that combat disease.

[matthew.j.bottomley@gsk.com](mailto:matthew.j.bottomley@gsk.com)